PDCD1 and hypothyroidism: The prevalence of hypothyroidism, hypoadrenocorticism, and hypopituitarism was higher among the participants who received ipilimumab plus a PD-1 inhibitor; among participants who received ICI alone, the prevalence of any type of hypothyroidism was higher in participants treated with atezolizumab, nivolumab, and pembrolizumab in this order.